相似文献
1
Spike Protein-Fibrinogen Interaction: A Novel Immune Evasion Strategy of SARS-CoV-2?
ACS Pharmacol Transl Sci. 2025 Mar 19;8(4):1182-1184. doi: 10.1021/acsptsci.5c00122. eCollection 2025 Apr 11.
2
Antibody tests for identification of current and past infection with SARS-CoV-2.
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2.
3
Determinants of susceptibility to SARS-CoV-2 infection in murine ACE2.
J Virol. 2025 Jun 17;99(6):e0054325. doi: 10.1128/jvi.00543-25. Epub 2025 May 12.
4
Exploring Diverse Binding Mechanisms of Broadly Neutralizing Antibodies S309, S304, CYFN-1006 and VIR-7229 Targeting SARS-CoV-2 Spike Omicron Variants: Integrative Computational Modeling Reveals Balance of Evolutionary and Dynamic Adaptability in Shaping Molecular Determinants of Immune Escape.
bioRxiv. 2025 Apr 17:2025.04.15.649027. doi: 10.1101/2025.04.15.649027.
5
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
6
The pan-variant potential of light: 425 nm light inactivates SARS-CoV-2 variants of concern and non-cytotoxic doses reduce viral titers in human airway epithelial cells.
mSphere. 2025 Jun 25;10(6):e0023025. doi: 10.1128/msphere.00230-25. Epub 2025 May 28.
7
Dihydrotanshinone I targets the spike N-terminal domain to inhibit SARS-CoV-2 entry and spike-induced inflammation.
Phytomedicine. 2025 Sep;145:156989. doi: 10.1016/j.phymed.2025.156989. Epub 2025 Jun 17.
8
Physical interventions to interrupt or reduce the spread of respiratory viruses.
Cochrane Database Syst Rev. 2023 Jan 30;1(1):CD006207. doi: 10.1002/14651858.CD006207.pub6.
9
Quantitative characterisation of extracellular vesicles designed to decoy or compete with SARS-CoV-2 reveals differential mode of action across variants of concern and highlights the diversity of Omicron.
Cell Commun Signal. 2025 Jul 2;23(1):323. doi: 10.1186/s12964-025-02223-x.
10
The impact of clade B lineage 5 MERS coronaviruses spike mutations from 2015 to 2023 on virus entry and replication competence.
bioRxiv. 2025 Jul 1:2025.06.30.662263. doi: 10.1101/2025.06.30.662263.
本文引用的文献
1
SARS-CoV-2 evolution on a dynamic immune landscape.
Nature. 2025 Mar;639(8053):196-204. doi: 10.1038/s41586-024-08477-8. Epub 2025 Jan 29.
2
Fibrin drives thromboinflammation and neuropathology in COVID-19.
Nature. 2024 Sep;633(8031):905-913. doi: 10.1038/s41586-024-07873-4. Epub 2024 Aug 28.
3
Accurate structure prediction of biomolecular interactions with AlphaFold 3.
Nature. 2024 Jun;630(8016):493-500. doi: 10.1038/s41586-024-07487-w. Epub 2024 May 8.
4
Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses.
Nat Rev Immunol. 2023 Mar;23(3):189-199. doi: 10.1038/s41577-022-00784-3. Epub 2022 Sep 27.
5
SARS-CoV-2 variants of concern: spike protein mutational analysis and epitope for broad neutralization.
Nat Commun. 2022 Aug 18;13(1):4696. doi: 10.1038/s41467-022-32262-8.
6
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.
Cell. 2021 Apr 29;184(9):2332-2347.e16. doi: 10.1016/j.cell.2021.03.028. Epub 2021 Mar 16.
7
Neutralizing antibodies targeting SARS-CoV-2 spike protein.
Stem Cell Res. 2020 Dec 15;50:102125. doi: 10.1016/j.scr.2020.102125.
8
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
Science. 2020 Aug 7;369(6504):650-655. doi: 10.1126/science.abc6952. Epub 2020 Jun 22.
9
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.
Cell. 2020 Apr 16;181(2):281-292.e6. doi: 10.1016/j.cell.2020.02.058. Epub 2020 Mar 9.
10
PRODIGY: a web server for predicting the binding affinity of protein-protein complexes.
Bioinformatics. 2016 Dec 1;32(23):3676-3678. doi: 10.1093/bioinformatics/btw514. Epub 2016 Aug 8.
Zotero 插件